The construction projects, which have already begun, will be finalised gradually from the end of 2027 through 202
Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
Nadda underlined that India’s policy framework is aligned with this transformation
The clinical program has benefited from extensive European Union support, including the IMI2 TRIC-TB and UNITE4TB projects, as well as funding from the EDCTP2 bEto-TB project
The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
Subscribe To Our Newsletter & Stay Updated
